Topical Sevoflurane for Treatment of Chronic Leg Ulcers

Leg Ulcer Clinical Trial

Official title:

Analgesic and Healing Effect of Topical Sevoflurane for Chronic Venous Ulcers

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05303805
• Other study ID #: Sevoflurane in ulcers
• Status: Recruiting
• Phase: Phase 4
• Start date: May 2, 2022
• Est. completion date: January 31, 2025

Study information

• Verified date: September 2023
• Source: Charles University, Czech Republic
• Contact: Jiri Malek, M.D.
• Phone: +4202671622461
• Email: malekj[@]fnkv.cz
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded randomized study. The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be carried out in the standard manner. The duration of the study will be 5 days; if the defect heals earlier, it will be terminated early.

Exclusion criteria: allergy to sevoflurane, inability to understand the questionnaire

Parameters to be monitored will be pain intensity, microbial colonization, appearance and size of the defect

Description:

A prospective single-blinded randomized study will be conducted in patients of the Dermatovenereology Clinic of the 3rd Medical Faculty of Charles University (3LF UK) and the University Hospital Kralovske Vinohrady (FNKV) with painful non-healing tibial ulcers. Pain intensity on a numerical rating scale (NRS 0-10) must be NRS>4. The envelope method will be used for randomization. To blind patients, therapy will be performed by separating patients with a drape from the treatment area of the body. As sevoflurane has a typical odor, it will only be used in the control group to soak up absorbent material held under the distal pole of the wound without skin contact. In the active treatment group, sevoflurane will be applied at the beginning of the wound treatment at approximately 1 ml/cm2 of the ulcer surface. The standard therapy used in the control group will use only Cyteal TM lavage solution, which contains hexamidine diisetione 100 mg in 100 ml, chlorhexidine digluconate 20% solution 100 mg and chlorocresol 300 mg.

The primary aim of the study will be pain relief after sevoflurane therapy. Pain intensity will be measured by NRS at 1-hour intervals (excluding sleep); decrease of 2 point for at least 4 hours will be considered significant. Secondary aim will be healing of ulcers. The effect will be controlled by elimination of pathologic microbial colonization, cleaning of the base of the wound and decreasing the size of the ulcer. Microbial colonization will be measured by microbial swab culture before application, after the 1st application before dressing and on the 5th day after application), the appearance of the defect base will be assessed by the appearance of the surface, the size of the defect will be measured in cm2.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: January 31, 2025
• Est. primary completion date: April 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with painful (pain intensity on the numerical scale NRS 0-10 is NRS>4) non- healing tibial venous ulcers

Exclusion Criteria:

• Allergy to sevoflurane

• Inability to understand the pain-intensity questionnaire

Related Conditions & MeSH terms

• Leg Ulcer
• Ulcer

Intervention

Drug:
• Sevoflurane
Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.

Combination Product:
• Cyteal
Rinsing and cleaning of ulcer.

Locations

Country	Name	City	State
Czechia	Faculty Hospital Kralovske Vinohrady	Praha

Sponsors (2)

Lead Sponsor	Collaborator
Charles University, Czech Republic	Faculty Hospital Kralovske Vinohrady

Country where clinical trial is conducted

Czechia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain intensity	Pain intensity measured by numeric rating scale (NRS) from 0 - no pain (the best result) to 10 - the worst possible pain using a standard questionnaire	Continuously for 5 days
Secondary	Microbial colonization	Microbial smear for culture	Before application of treatment, after the 1st application before tibial coverage and on the 5th day after application
Secondary	Size of skin defect	Measured in cm2	5 days
Secondary	Appearance of the ulcer bed	Epithelial tissue, granulation tissue, slough, necrotic tissue	5 days